Long-Term Outcomes of In-Stent Restenosis With BMS
. Study design. Primary endpoint: major adverse cardiac events after follow-up coronary angiography including all-cause death, acute coronary syndrome and target lesion revascularization. In-stent restenosis (ISR), >50% diameter stenosis (DS) on angiography. CAD, coronary artery disease; BMS, baremetal stent. raphy in subjects with and without ISR.
Primary Endpoint
The primary endpoints of the present study were major adverse cardiac events (MACE) defined as a composite of all-cause death, ACS and target lesion revascularization (TLR) during the follow-up period. The patients were clinically followed up by monitoring clinic attendance charts, via telephone contact and by sending questionnaires to the patients or their families. Mortality data were collected from the medical records of patients who died or who were treated at Juntendo University Hospital, and from other hospitals where patients were admitted (they were asked to provide details and causes of death). Mortality data were categorized as death from all causes or cardiovascular death including death from coronary artery disease (CAD), cardiogenic shock, stroke and sudden death. We defined ACS among patients with acute myocardial infarction (AMI) and unstable angina pectoris (UAP). AMI was defined as the presence of ischemic symptoms and a 2-fold increase in creatine kinase. UAP was diagnosed in the presence of ischemic symptoms regardless of ST-T changes. TLR was defined as repeat revascularization clinically driven by any lesion in the stented segment. First TLR at the time of follow-up angiography was excluded, therefore TLR in the present study included re-TLR with repeat revascularization 
Clinical Parameters
Clinical presentation, demographic data, coronary risk factors and medication use were recorded in the Juntendo University Hospital database. Blood samples were obtained during the early morning after an overnight fast. Blood pressure (BP) was measured at the time of admission. Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) <60 ml · min -1 · 1.73 m -2 calculated using the modification of diet in renal disease (MDRD) equation modified with a Japanese coefficient using baseline serum creatinine. 13 Diabetes mellitus was defined as fulfilling at least 1 criterion of either hemoglobin A1c (HbA1c) >6.1% or undergoing treatment with anti-diabetic agents such as insulin or oral hypoglycemic drugs. Patients with BP >140/90 mmHg or taking anti-hypertensive drugs were regarded as hypertensive and those with total cholesterol >220, or taking statins and/or lipid-lowering agents were regarded as dyslipidemic. Written informed consent was obtained from all patients before coronary intervention. The internal review board approved the study, which proceeded according to the Declaration of Helsinki.
Statistical Analysis
Quantitative data are presented as mean ± SD. Patient characteristics were compared between the groups with and without ISR. Continuous variables were compared using an unpaired t-test or Mann-Whitney U-test. Categorical variables (presented as frequencies) were compared using either chi-squared statistics or Fisher's exact probability test. Event-free survival rates between the 2 groups were compared by constructing Kaplan-Meier curves and using the log-rank test. Multivariate Cox regression analysis was applied to determine whether ISR was associated with adverse events even after adjusting for confounding factors including age, multivessel disease, diabetes, current smoking, prior myocardial infarction, prior PCI, left ventricular ejection fraction, HbA1c, eGFR and insulin usage. Marginally different characteristics (P<0.10) on uni- variate analysis were defined as confounding factors. All variables were simultaneously adjusted in 1 step. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. P<0.05 was considered to indicate statistical significance. All data were analyzed using SPSS version 18.0 for Windows (SPSS, Chicago, IL, USA).
Results

Baseline and Procedural Characteristics
The median follow-up period was 2,214 days (interquartile range, 1,878-2,806 days). Of the 746 patients included in the final analysis, 215 (28.8%) had ISR at follow-up angiography (ISR group). 
Discussion
The major findings in the present study on long-term outcomes Tables 1,2 . Long-Term Outcomes of In-Stent Restenosis With BMS in patients with ISR were as follows. ISR identified a group of patients who were at high risk of future events in the long term (>6 years); the rates of ACS and TLR were consistently higher in the ISR group and the association between ISR after BMS implantation and long-term clinical outcomes remained statistically significant even after adjusting for potential confounding factors. The restenosis of BMS has historically been regarded as a benign clinical process. Some recent reports, however, have found that ACS occurs in approximately 50% of patients with BMS restenosis. 14, 15 The rate of ACS at presentation of restenosis, although relatively low (3.8-18%) in Japan (which might be associated with the routine follow-up angiography and frequent use of intravascular ultrasound for PCI), is nevertheless frequent. 16, 17 The present study found that the rate of ACS at presentation among 215 ISR patients was 7.4%, which is comparable to previous reports from Japan.
Neointimal hyperplasia peaked up to 6 months after BMS implantation (early restenosis phase), then regressed (intermediate regression phase), and then a late luminal narrowing phase occurred after 4 years. 8, 18 A very long-term clinical and angiographic follow-up after BMS implantation has suggested that luminal re-narrowing of stented segments is a process that develops over 10 years; this corresponds to the rate of late TLR that increases at 15 years (24.7%). 19 In addition, that study also found that 38% of late TLR was driven by severe angina or AMI. One report describes a 10-year incidence of clinical restenosis of 18.1% and a 2.1% incidence of presenting with AMI. 20 The present study found a consistently higher rate of ACS in the ISR group. Several possible explanations for this should be considered. The accumulation of smooth muscle cells within neointimal hyperplasia leads to plaque expansion by an increase in the extracellular matrix and thrombus formation, which plays an important role in ACS. 21 Another possible mechanism of ACS presentation might be a rapid conformational change in a lesion due to the proliferation of smooth muscle cells that could contribute to a relatively rapid and abrupt onset of luminal narrowing. With regard to ACS that arises during the late phase, emerging histopathological evidence supports the formation of late neoatherosclerotic plaque within stented segments after 5 years; 22 and unstable lesions characterized as thin-cap fibroatheromas or plaque rupture have also been observed. 23 Coronary imaging using optical coherence tomography has shown that neointima within BMS transforms into lipid-laden tissue at >5 years after stent implantation and that neovascularization expanding into the intra-intima might contribute to the atherosclerotic progression of neointima. 24 These findings suggest that BMS restenosis presenting with ACS long after implantation might be attributable to plaque rupture within the neointima.
The cumulative incidence of TLR after follow-up coronary angiography reached a plateau after 1 year in the present study, suggesting that the cause of ACS was predominantly a non-target lesion (Table 3 ). In addition, the higher TLR rate was observed in patients with repeat revascularization in the ISR group (30/136, 22%) compared with ISR patients without repeat revascularization (3/79, 3.8%), suggesting that higher TLR in the ISR group was predominantly due to re-restenosis. After the introduction of DES with remarkable efficacy for restenosis, DES has become the treatment of choice for BMS restenosis patients. 25, 26 In most of the present study period, however, DES was not available in Japan. Therefore, POBA, especially cutting balloon, was widely used for BMS restenosis, which resulted in a relatively higher TLR rate. We also confirmed that the established classical risks of BMS restenosis such as age and diabetes were significantly higher in the ISR group. In particular, the presence of diabetes affects mortality rates due to CAD more than its absence. 27, 28 Others have demonstrated that diabetes mellitus is associated with accelerated development of atherosclerosis characterized by small vessels, long lesions and a greater plaque burden. Restenosis and disease progression equally contribute to repeated revascularization in diabetic patients. 29 Multivariate Cox regression analysis showed that ISR is a more powerful predictor of longterm clinical outcomes than diabetes after adjusting for confounding factors. Therefore, we believe that ISR should be considered as a high-risk clinical entity and a possible predictor of atherosclerotic progression, as well as diabetes, and that careful management and more aggressive intervention are required to improve long-term prognosis.
Study Limitations
This was a single-center, retrospective observational study of a small patient cohort, and thus unknown confounding factors might have affected the outcomes regardless of the adjusted analysis. We might not have captured all adverse events, which could have resulted in underestimation of events during follow-up. In addition, the duration of follow-up was relatively shorter than that in some published reports.
Conclusions
The ISR of BMS was significantly associated with long-term adverse clinical outcomes, suggesting that this is not a benign clinical entity, although these patients had optimal medical treatment with evidence-based medicine, as did patients without ISR. Careful consideration of the risks of ISR for future cardiovascular events is required.
